Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PRP

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    196 result(s) found for: PRP. Displaying page 5 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-005547-24 Sponsor Protocol Number: HXM01C Start Date*: 2013-03-07
    Sponsor Name:Sanofi Pasteur MSD
    Full Title: A phase III open-label randomised study to evaluate the immunogenicity and safety of the concomitant administration of a new Hexavalent DTaP-IPV-HepB-PRP-T combined vaccine (Hexavalent vaccine) giv...
    Medical condition: Healthy infants 46 to 74 days of age (both inclusive)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10054187 Polio immunization LLT
    17.0 100000004865 10069543 Hemophilus influenzae type b immunization LLT
    17.0 100000004865 10069593 Pertussis immunization LLT
    17.0 100000004865 10054181 Hepatitis B immunization LLT
    17.0 100000004865 10054180 Diphtheria immunization LLT
    17.0 100000004865 10054183 Tetanus immunization LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-001095-21 Sponsor Protocol Number: A5I16 Start Date*: 2016-04-19
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed),...
    Medical condition: Pertussis, adsorbed diphtheria and tetanus toxoids, inactivated poliomyelitis and polysaccharide of H. influenza type b bound to tetanus toxoid
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-005577-43 Sponsor Protocol Number: 116194 Start Date*: 2016-08-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open-label study to assess the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course at 3, 4.5 and 6 months...
    Medical condition: Healthy volunteers (immunisation against diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003459-39 Sponsor Protocol Number: HIB-MENCY-TT-016 Start Date*: 2015-07-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open, randomized, controlled, multicenter study to assess the co-administration of Rotarix (GlaxoSmithKline Biologicals’) with Hib-MenCY-TT (GlaxoSmithKline Biologicals’ Meningococcal...
    Medical condition: invasive diseases caused by Haemophilus influenzae type b (Hib) and Neisseria meningitidis serogroups C (MenC) and Y (MenY)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003451-38 Sponsor Protocol Number: OVG2018/05 Start Date*: 2019-02-21
    Sponsor Name:Clinical Trials and Research Governance (CTRG)
    Full Title: Immunogenicity and reactogenicity of concomitantly administered hexavalent and Group B meningococcal vaccines in infancy.
    Medical condition: Immunogenicity and reactogenicity of concomitantly administered hexavalent and group B meningococcal vaccines in infancy.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-005529-74 Sponsor Protocol Number: ML19982 Start Date*: 2006-03-16
    Sponsor Name:Roche (Hungary) Ltd.
    Full Title: A randomised, open-label, multi-national, multi-center study to investigate the impact of bone-marker feedback (at 3 months) on adherence to once monthly ibandronate treatment of patients with post...
    Medical condition: osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10031282 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SI (Completed) SK (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-000876-33 Sponsor Protocol Number: 114843 Start Date*: 2011-08-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, double-blind, multicentre study to evaluate the safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in heal...
    Medical condition: Healthy volunteers (toddlers): Booster immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10043376 Tetanus PT
    14.0 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    14.0 10021881 - Infections and infestations 10034738 Pertussis PT
    14.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    14.0 10021881 - Infections and infestations 10013023 Diphtheria PT
    14.0 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002639-14 Sponsor Protocol Number: VGFTe-OD-1411 Start Date*: 2016-12-29
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
    Medical condition: NonProliferative Diabetic Retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003508-12 Sponsor Protocol Number: 010-01 Start Date*: 2006-02-28
    Sponsor Name:Merck and Co., Inc.
    Full Title: Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children
    Medical condition: RotaTeq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, G4, and G-serotypes that contain P1 (e.g...
    Disease: Version SOC Term Classification Code Term Level
    10 10017913 LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002352-18 Sponsor Protocol Number: 103813,105067 Start Date*: 2015-06-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, multinational study, double-blinded for the immunogenicity and consistency evaluation of 3 Hib-MenCY-TT vaccine lots and single-blinded and controlled for the evaluation of...
    Medical condition: Invasive disease caused by Haemophilus type b and Neisseria meningitidis serogroups C and Y
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028910 Neisseria meningitides meningitis LLT
    18.0 100000004862 10051931 Neisseria infection NOS LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004431-31 Sponsor Protocol Number: A3L04 Start Date*: 2012-04-10
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Phase III, randomized, blind-observer, multi-center, four-arm, parallel-group trial in 2133 infants
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    14.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004133-17 Sponsor Protocol Number: A5I15 Start Date*: 2006-01-19
    Sponsor Name:Sanofi Pasteur Incorporated
    Full Title: A randomised, controlled, double blind study of the immunogenicity and safety of Pediacel™, a combined diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemoph...
    Medical condition: PEDIACEL® is a fully liquid combination vaccine indicated for infants from 2 months of age to protect against diseases caused by 5 common pathogens: Haemophilus influenzae type b, Corynebacterium d...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002650-67 Sponsor Protocol Number: IBERepic/2018 Start Date*: 2018-11-15
    Sponsor Name:Ibermutuamur (Mutua Colaboradora con la Seguridad Social nº 274)
    Full Title: Comparison of the efficacy of autologous platelet rich plasma injections, and extracorporeal shock wave therapy, in the treatment of work –related lateral epicondylitis.
    Medical condition: The epicondylitis is an overuse injury, in most cases, is a self-limited course and responds well to conservative treatment. Its etiology is degenerative and is related to a repetitive overuse and ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000575-32 Sponsor Protocol Number: 1 Start Date*: 2018-12-18
    Sponsor Name:Isabel Maria Ruiz
    Full Title: Results of the injection of botulinum toxin vs platelet rich plasma for the treatment of plantar fasciitis
    Medical condition: Plantar fasciitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10035155 Plantar fasciitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003042-16 Sponsor Protocol Number: IIBSP-PTE-2018-35 Start Date*: 2019-02-08
    Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau
    Full Title: Randomized clinical trial to evaluate the efficacy of fibrin membrane graft with eye drops concentrated in autologous growth factors in primary pterygium surgery comparing it with amniotic membrane...
    Medical condition: Pterigyum
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003943-32 Sponsor Protocol Number: DORO001 Start Date*: 2015-08-06
    Sponsor Name:Charité University Medicine Berlin
    Full Title: Influence of diabetes control on treatment of diabetic macular edema with ranibizumab
    Medical condition: Diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000865-33 Sponsor Protocol Number: HUA_AFF_PRP_21 Start Date*: 2021-10-05
    Sponsor Name:INSTITUTO DE INVESTIGACIÓN SANITARIA BIOARABA
    Full Title: Randomized, parallel controlled study with routine clinical practice to evaluate the efficacy and tolerability of PRFC ENDORET® in the treatment of frontal fibrosing alopecia
    Medical condition: • Patients diagnosed with fibrosing frontal alopecia (FFA) with an age greater than or equal to 18 years. • Patient not responding to previous treatments for at least 6 months. • Use of effective...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003952-63 Sponsor Protocol Number: LIQUENIA Start Date*: 2017-07-07
    Sponsor Name:Instituto de Investigación Sanitaria La Fe
    Full Title: Pilot study of vulval lichen sclerosus treatment by adipose tissue associated with autologous platelet-rich plasma
    Medical condition: Vulval lichen sclerosus
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10047761 Vulval lichen sclerosus et atrophicus LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002129-39 Sponsor Protocol Number: XC.ROD.2017 Start Date*: 2017-08-02
    Sponsor Name:XCELL Medical Solutions
    Full Title: Phase II Clinical Trial to Know the effectiviness and safety with a a treatment based in a therapy with serical autologous white cells versus the use of Platelet Rich Plasma in patients with rotu...
    Medical condition: Patients with Rotulian Tendinopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10043237 Tendon, ligament and cartilage disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-006817-12 Sponsor Protocol Number: 2031-38 Start Date*: 2022-06-24
    Sponsor Name:ASSITANCE PUBLIQUE HOPITAUX DE MARSEILLE
    Full Title: Evaluation of the efficacy of an intra-articular injection of autologous microfat combined with autologous platelet-enriched plasma in the treatment of radiocarpal osteoarthritis: a randomized cont...
    Medical condition: radiocarpal osteoarthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 13:20:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA